Veeva Systems Inc. (NYSE:VEEV - Get Free Report) EVP Alan Mateo sold 3,391 shares of the company's stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $200.86, for a total transaction of $681,116.26. Following the transaction, the executive vice president now owns 21,983 shares in the company, valued at approximately $4,415,505.38. The sale was disclosed in a filing with the SEC, which is available at this link.
Veeva Systems Stock Performance
VEEV stock opened at $200.95 on Wednesday. The firm has a market cap of $32.42 billion, a PE ratio of 62.41, a P/E/G ratio of 2.00 and a beta of 0.74. The firm's fifty day moving average is $220.53 and its 200 day moving average is $202.75. Veeva Systems Inc. has a one year low of $160.21 and a one year high of $236.90.
Veeva Systems (NYSE:VEEV - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. The company had revenue of $630.62 million for the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. Research analysts predict that Veeva Systems Inc. will post 4.11 earnings per share for the current fiscal year.
Analyst Ratings Changes
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
VEEV has been the topic of a number of recent analyst reports. Robert W. Baird upped their price target on shares of Veeva Systems from $245.00 to $251.00 and gave the company an "outperform" rating in a research note on Friday, March 1st. KeyCorp upped their price target on shares of Veeva Systems from $232.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, March 5th. Barclays upped their price target on shares of Veeva Systems from $240.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, March 1st. Oppenheimer restated an "outperform" rating and set a $225.00 price target on shares of Veeva Systems in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $250.00 price target on shares of Veeva Systems in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Veeva Systems currently has a consensus rating of "Moderate Buy" and an average target price of $234.90.
Read Our Latest Research Report on Veeva Systems
Institutional Trading of Veeva Systems
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in Veeva Systems during the third quarter valued at $25,000. Operose Advisors LLC purchased a new position in Veeva Systems during the third quarter valued at $29,000. DSM Capital Partners LLC purchased a new position in Veeva Systems during the fourth quarter valued at $29,000. Vermillion & White Wealth Management Group LLC purchased a new position in Veeva Systems during the fourth quarter valued at $32,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Veeva Systems by 81.9% during the third quarter. Parkside Financial Bank & Trust now owns 171 shares of the technology company's stock valued at $35,000 after purchasing an additional 77 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company's stock.
Veeva Systems Company Profile
(
Get Free Report)
Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
